12:00 AM
 | 
Aug 03, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AP24534: Preliminary Phase I data

In a dose-escalation, U.S. Phase I trial in 32 evaluable patients, AP24534 showed significant anti-tumor activity in highly resistant CML patients. There was no evidence of disease progression in 19 of 23 patients in the 4...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >